Prescient Therapeutics (ASX: PTX) tops-up cash reserves to progress innovative cancer therapies (w/ Steven Yatomi-Clarke)

Prescient Therapeutics (ASX: PTX) managing director and chief executive officer Steven Yatomi-Clarke joins Small Caps to discuss the company’s plans for its innovative cancer therapies PTX-100 and PTX-200. Prescient launched an $8 million capital raising last month to fund the progression of the two therapies towards first in-human clinical studies. The company is also advancing its next generation OmniCAR CAR-T platform for fighting cancer, which it says can do what conventional CAR-T cannot. Articles:https://smallcaps.com.au/prescient-therapeutics-enters-strategic-collaboration-renowned-cancer-centre-us/https://smallcaps.com.au/prescient-therapeutics-progress-innovative-pipeline-cancer-treatments-capital-raise/https://smallcaps.com.au/prescient-therapeutics-signs-deal-q-gen-omnicar-clinical-trials/ For more information on Prescient Therapeutics : https://smallcaps.com.au/stocks/PTX/ See omnystudio.com/listener for privacy information.